Navegando por Palavras-chave "Braf(V600e) Mutation"

Agora exibindo 1 - 1 de 1
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants
    (Oxford univ press inc, 2016) Shi, Xiaoguang; Liu, Rengyun; Basolo, Fulvio; Giannini, Riccardo; Shen, Xiaopei; Teng, Di; Guan, Haixia; Shan, Zhongyan; Teng, Weiping; Musholt, Thomas J.; Al-Kuraya, Khawla; Fugazzola, Laura; Colombo, Carla; Kebebew, Electron; Jarzab, Barbara; Czarniecka, Agnieszka; Bendlova, Bela; Sykorova, Vlasta; Sobrinho-Simoes, Manuel; Soares, Paula; Shong, Young Kee; Kim, Tae Yong; Cheng, Sonia; Asa, Sylvia L.; Viola, David; Elisei, Rossella; Yip, Linwah; Mian, Caterina; Vianello, Federica; Wang, Yangang; Zhao, Shihua; Oler, Gisele [UNIFESP]; Cerutti, Janete Maria [UNIFESP]; Puxeddu, Efisio; Qu, Shen; Wei, Qing; Xu, Huixiong; O'Neill, Christine J.; Sywak, Mark S.; Clifton-Bligh, Roderick; Lam, Alfred K.; Riesco-Eizaguirre, Garcilaso; Santisteban, Pilar; Yu, Hongyu; Tallini, Giovanni; Holt, Elizabeth H.; Vasko, Vasily; Xing, Mingzhao
    Context: Individualized management, incorporating papillary thyroid cancer (PTC) variant-specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive data demonstrating differential risks of PTC variants to support. Objective: This study sought to establish the differential clinicopathological risk of major PTC variants: conventional PTC (CPTC), follicular-variant PTC (FVPTC), and tall-cell PTC (TCPTC). Methods: This was a retrospective study of clinicopathological outcomes of 6282 PTC patients (4799 females and 1483 males) from 26 centers and The Cancer Genome Atlas in 14 countries with a median age of 44 years (interquartile range, 33-56 y) and median follow-up time of 37 months (interquartile range, 15-82 mo). Results: The cohort consisted of 4702 (74.8%) patients with CPTC, 1126 (17.9%) with FVPTC, and 239 (3.8%) with TCPTC. The prevalence of high-risk parameters was significantly different among the three variants, including extrathyroidal invasion, lymph node metastasis, stages III/IV, disease recurrence, mortality, and the use (need) of radioiodine treatment (all P < .001), being highest in TCPTC, lowest in FVPTC, and intermediate in CPTC, following an order of TCPTC > CPTC >> FVPTC. Recurrence and mortality in TCPTC, CPTC, and FVPTC were 27.3 and 6.7%, 16.1 and 2.5%, and 9.1 and 0.6%, corresponding to events per 1000 person-years (95% confidence interval [CI]) of 92.47 (64.66-132.26) and 24.61 (12.31-49.21), 34.46 (30.71-38.66), and 5.87 (4.37-7.88), and 24.73 (18.34-33.35) and 1.68 (0.54-5.21), respectively. Mortality hazard ratios of CPTC and TCPTC over FVPTC were 3.44 (95% CI, 1.07-11.11) and 14.96 (95% CI, 3.93-56.89), respectively. Kaplan-Meier survival analyses showed the best prognosis in FVPTC, worst in TCPTC, and intermediate in CPTC in disease recurrence-free probability and disease-specific patient survival. This was particularly the case in patients at least 45 years old. Conclusion: This large multicenter study demonstrates differential prognostic risks of the three major PTC variants and establishes a unique risk order of TCPTC > CPTC >> FVPTC, providing important clinical implications for specific variant-based management of PTC.